Product review on the Anti-PD-L1 antibody atezolizumab

Neil J. Shah, William J. Kelly, Stephen V. Liu, Karin Choquette, Alexander Spira

Research output: Contribution to journalReview articlepeer-review

Abstract

Immunotherapy as a therapeutic strategy has seized the narrative throughout clinical oncology over the past few years. Once considered a niche treatment for rare cancers, immunotherapy has quickly emerged as the standard of care for many common cancer types. The remarkable rise is largely due to the development of novel checkpoint inhibitors, specifically, antibodies targeting PD-1 and PD-L1. Offering promising efficacy with a favorable toxicity profile, these agents have been approved for use in several malignancies and are under investigation for many more. One of the more appealing features is the chance for meaningful, durable response – uncharacteristic for most cancer therapies. Atezolizumab is a humanized IgG1 monoclonal antibody that targets PD-L1. Atezolizumab has been approved for use in the treatment of advanced non-small cell lung cancer (NSCLC) and bladder cancer and has shown promising activity in several other types of cancer. Here, we provide a product review for atezolizumab.

Original languageEnglish (US)
Pages (from-to)269-276
Number of pages8
JournalHuman Vaccines and Immunotherapeutics
Volume14
Issue number2
DOIs
StatePublished - Feb 1 2018
Externally publishedYes

Keywords

  • Atezolizumab
  • Bladder cancer
  • Immunothrapy
  • Lung cancer
  • Pdl-1

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Fingerprint Dive into the research topics of 'Product review on the Anti-PD-L1 antibody atezolizumab'. Together they form a unique fingerprint.

Cite this